Apollo Hospitals Enterprise Limited has announced the completion of a significant acquisition by its subsidiary Imperial Hospital and Research Centre Limited. The healthcare giant disclosed that Imperial Hospital has acquired Belenus Champion Hospitals Private Limited for a total consideration of Rs 1,650 million, marking a strategic expansion in the Bangalore healthcare market.

Acquisition Details

The acquisition structure involves Imperial Hospital and Research Centre Limited, in which Apollo Hospitals holds a 90% equity stake, purchasing 6,48,468 equity shares of Belenus Champion Hospitals Private Limited. The transaction details are as follows:

The total acquisition cost of Rs 1,650 million includes the equity value and settlement of existing liabilities. Following this transaction, Belenus Champion Hospitals Private Limited has become a wholly owned subsidiary of Imperial Hospital and Research Centre Limited and a step-down subsidiary of Apollo Hospitals.

Hospital Expansion Plans

Belenus operates a 125-bed hospital facility located on Marathahalli Road, Bangalore, under the brand name "Belenus Champion Hospital." The company has outlined ambitious expansion plans for the acquired facility:

The hospital is currently undergoing upgrades and expansion, with the facility set to reopen as a fully upgraded 175-bed multi-speciality hospital. The overall investment, including the initial acquisition cost of Rs 1,650 million, will total Rs 3,000 million.

Financial Performance of Acquired Entity

Belenus Champion Hospitals Private Limited, incorporated on 8th December 2021, has demonstrated varying financial performance over the past three years:

The company's revenue from operations for the financial year ended March 31, 2025, was Rs 274.90 million. The acquisition aligns with Apollo Hospitals' strategy to expand its hospital operations and strengthen its healthcare presence across key markets.

Strategic Implications

The acquisition represents Apollo Hospitals' continued focus on expanding its healthcare network through strategic investments. The transaction does not fall within the ambit of related party transactions, and no promoter group companies have any interest in the acquired entity. The deal was completed through cash consideration and required no governmental or regulatory approvals.

This expansion into Bangalore's healthcare market through the upgraded facility positions Apollo Hospitals to serve a broader patient base in one of India's key metropolitan areas. The investment demonstrates the company's commitment to enhancing healthcare infrastructure and services across the country.

Apollo Hospitals Enterprise Limited has delivered impressive financial results for Q3FY26, demonstrating strong growth momentum across its integrated healthcare platform. The company announced its unaudited financial results for the three and nine months ended December 31, 2025, showcasing robust performance in all business verticals.

Financial Performance Highlights

The company's consolidated performance for Q3FY26 showed remarkable growth across key metrics:

For the nine-month period ended December 31, 2025, the consolidated results continued to reflect strong performance:

Interim Dividend Declaration

The Board of Directors declared an interim dividend of Rs. 10 per share, representing 200% of the face value of Rs. 5 per share for the financial year 2025-26. The key dates for the dividend payment are:

Segment-wise Performance

Healthcare Services (Hospitals)

The healthcare services division maintained strong growth with revenue of Rs. 31,832 million in Q3FY26 compared to Rs. 27,850 million in Q3FY25, representing 14% YoY growth. EBITDA increased 18% YoY to Rs. 7,898 million with margins at 24.8%. The division operates 8,072 beds across the network with an overall occupancy rate of 67%.

Apollo Health and Lifestyle Limited

The diagnostics and retail healthcare segment showed robust performance with revenue growing 20% YoY to Rs. 4,668 million. EBITDA improved significantly by 39% to Rs. 476 million, with margins expanding to 10.2%.

Apollo HealthCo

The digital healthcare and pharmacy distribution platform delivered strong results with revenue growing 20% YoY to Rs. 28,274 million. EBITDA increased substantially to Rs. 1,279 million compared to Rs. 566 million in the previous year, with margins at 4.5%. The platform added 185 net new stores during the quarter, bringing the total to 7,113 stores.

Operational Milestones

Apollo Hospitals launched a cutting-edge 250-bed quaternary care hospital in Pune, representing the first phase of a planned 400-bed capacity. The facility features advanced surgical robotics, precision oncology, and comprehensive critical care with 100+ ICU beds.

The company continues to lead in transplant care as the world's busiest solid organ transplant program, performing an average of five solid organ transplants daily. The group has completed over 21,000 kidney transplants and more than 5,000 liver transplants, becoming the first hospital group in India to reach this milestone.

Regulatory Impact

The company reported an exceptional item of Rs. 192 million in consolidated results due to the implementation of new Labour Codes notified by the Government of India on November 21, 2025. This one-time impact resulted from increased gratuity and leave liabilities arising from the consolidation of twenty-nine existing labour laws into a unified framework.

Corporate Developments

The Board approved a Composite Scheme of Arrangement involving the demerger of identified business undertakings, primarily representing the omni-channel pharmacy distribution business and digital health platform business. The scheme has received necessary approvals from stock exchanges, and the company has filed an application before the National Company Law Tribunal for final approval.